InnoCare Pharma Limited: all 63 studies
Page 1 of 1. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingNCT07784101Phase 3
- A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's SyndromeNot yet recruitingNCT07727486Phase 2
- Evaluation of ICP-B208 in Patients With Advanced Solid TumorsRecruitingNCT07617493Phase 1/2
- Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy SubjectsRecruitingNCT07535099Phase 1
- Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind StudyRecruitingNCT07440537Phase 2
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous UrticariaRecruitingNCT07378527Phase 2/3
- Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT07251998Phase 2
- Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo NodularisRecruitingNCT07236099Phase 2
- Evaluation of ICP-B794 in Patients With Advanced Solid TumorsNot yet recruitingNCT07136558Phase 1
- A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)RecruitingNCT07082686Phase 2
- ICP-332 in Subjects With Non-segmental VitiligoRecruitingNCT07047612Phase 2/3
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin LymphomaNot yet recruitingNCT06845241Phase 1/2
- Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque PsoriasisRecruitingNCT06842199Phase 3
- ICP-332 in Subjects With Moderate to Severe Atopic DermatitisRecruitingNCT06775860Phase 3
- ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesRecruitingNCT06656494Phase 1
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Phase 3
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Phase 2/3
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Phase 3
- Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesRecruitingNCT06351527Phase 1
- Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06082102Phase 3
- Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06004856Phase 3
- Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System TumorsRecruitingNCT05745623Phase 1/2
- The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
- Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT05719701Phase 1/2
- Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT05702268Phase 2
- Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic MalignanciesRecruitingNCT05690581Phase 1
- Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus ErythematosusRecruitingNCT05688696Phase 2
- Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy SubjectRecruitingNCT05684653Phase 1
- A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT05678270Phase 2
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingNCT05552937Phase 2
- A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid TumorsNot yet recruitingNCT05370755Phase 1
- A Study of ICP-033 in Patients With Advanced Solid TumorsRecruitingNCT05367232Phase 1
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaRecruitingNCT05234684Phase 3
- A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid TumorsRecruitingNCT04685226Phase 1/2
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3
- An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial CancerRecruitingNCT04492293Phase 2
- Phase I Study of ICP-332 in Healthy SubjectsCompletedNCT06530966Phase 1
- Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque PsoriasisCompletedNCT06109818Phase 2
- Evaluating Different Doses of Orelabrutinib in MCLCompletedNCT05978739Phase 2
- Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy SubjectsStatus unknownNCT05660720Phase 1
- Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsStatus unknownNCT05537987Phase 1
- A Clinical Study of ICP-488 in Healthy Subjects and Patients With PsoriasisStatus unknownNCT05451199Phase 1
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy SubjectsCompletedNCT05399030Phase 1
- A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene AlterationsStatus unknownNCT05372120Phase 2
- DDI Study of OrelabrutinibCompletedNCT05316857Phase 1
- A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune ThrombocytopeniaStatus unknownNCT05232149Phase 2
- A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)Active, not recruitingNCT05210868Phase 1/2
- A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell LymphomaCompletedNCT05051891Phase 3
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04711148Phase 2
- A Study of ICP-192 in Patients With Advanced Solid TumorsStatus unknownNCT04565275Phase 1/2
- ADME Study of [14C]ICP-022 in Healthy MalesCompletedNCT04441450Not applicable
- A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaCompletedNCT04440059Phase 2
- A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSLStatus unknownNCT04438044Phase 2
- A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
- A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)CompletedNCT04305197Phase 1/2
- A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaActive, not recruitingNCT04304040Phase 1/2
- A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesActive, not recruitingNCT04014205Phase 1/2
- A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Phase 2
- Clinical Study of ICP-192 in Solid Tumors PatientsStatus unknownNCT03758664Phase 1/2
- Study of ICP-105 in Solid Tumors PatientsCompletedNCT03642834Phase 1
- A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)CompletedNCT03494179Phase 1/2
- A Study to Evaluate ICP-022 in Patients With CLL/ SLLStatus unknownNCT03493217Phase 1/2
- A Phase I Study of ICP-022 in Healthy SubjectsCompletedNCT03189017Phase 1